Vera's Trutakna posts durable kidney protection in IgA nephropathy Phase 3 results
TL;DR Summary
Vera Therapeutics reported final two-year Phase 3 results for Trutakna in IgA nephropathy, showing stabilized kidney function and a reduced risk of kidney-related death and other complications; with FDA accelerated approval granted in July, the company plans to pursue full FDA approval in Q4.
- Vera kidney drug Trutakna shows strong final results in Phase 3 trial STAT
- Positive data positions Vera's IgA nephropathy drug Trutakna for full approval FirstWord Pharma
- Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens — What Happened? Investor's Business Daily
- Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy finance.yahoo.com
- Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data hcplive.com
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
2 min
vs 3 min read
Condensed
91%
465 → 44 words
Want the full story? Read the original article
Read on STAT